Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of parathyroid hormone and alendronate [alendronic acid] in combination in the treatment of osteoporosis

X
Trial Profile

Clinical trial of parathyroid hormone and alendronate [alendronic acid] in combination in the treatment of osteoporosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alendronic acid (Primary) ; Parathyroid hormone (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms PaTH
  • Most Recent Events

    • 21 Oct 2020 According to an Ascendis Pharma media release, data from this trial will be presented at European Calcified Tissue Society (ECTS) 2020.
    • 10 Sep 2020 According to an Ascendis Pharma media release Dr. Khan is the primary investigator .
    • 10 Sep 2020 According to an Ascendis Pharma media release, results from the 4-week, fixed dose double-blinded portion of this trial will be presented at American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top